Firebrick Pharma (ASX:FRE) has appointed experienced pharmaceutical executive Nilesh Wadhwa to lead its global business development and licensing efforts as the company pushes to rapidly expand international approvals and sales of its Nasodine product range.
The Melbourne-based company announced the appointment following an international search, positioning Wadhwa to spearhead licensing partnerships and market-entry strategies to significantly increase the company’s geographic reach over the next three years.
Wadhwa brings three decades of experience in pharmaceutical partnering, international strategy, and commercial expansion. During his career, he has held senior roles across some of the world’s largest healthcare organisations, including Johnson and Johnson, Sanofi, Takeda Pharmaceuticals and Alembic Pharmaceuticals. His experience includes leading external innovation partnering initiatives across Asia, directing regional business development strategy across Asia Pacific, and driving international growth programs.
He has also negotiated and executed dozens of complex cross-border transactions spanning Asia Pacific, the United States and Europe, covering pharmaceuticals, medical devices and consumer health products.
Firebrick Executive Chairman Dr Peter Molloy said the appointment comes at an important moment as the company seeks to broaden the commercial footprint of its Nasodine portfolio.
“Nilesh joins us at a pivotal time in Firebrick’s development, as we seek to drive Nasodine approvals and licensing agreements in new markets across Asia Pacific and elsewhere,” Molloy said. “Our stated goal is to go from two products in just three countries to four products in up to 10 countries over the next three years; Nilesh will be key to achieving that goal.”
Wadhwa said he was enthusiastic about joining the company during a period of strategic expansion.
“I am thrilled to join Firebrick Pharma at such a crucial stage in its journey. The Company’s innovative portfolio and clear vision for international expansion present a unique opportunity, and I look forward to working with Peter and the team to drive commercial success and long-term value for our shareholders.”
The new role will take effect on 1 April 2026, with Wadhwa expected to relocate to Australia following a transition period over the coming months.
Firebrick Pharma develops and commercialises novel formulations and applications of povidone-iodine. Its flagship product, Nasodine nasal spray, is already available in the United States, Singapore, Fiji, and the South Pacific, with regulatory efforts underway in additional markets, including the Philippines. A follow-on product, Nasodine throat spray, has already been launched in Singapore and Fiji, as the company works to build a broader portfolio of up to 4 Nasodine-based products.